AZN:Datopotamab Deruxtecan Shows Favorable Survival Results, Falls Short Of Statistical Significance
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Overall survival results from the TROPION-Lung01 phase 3 trial numerically favored Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small
:max_bytes(150000):strip_icc():format(jpeg)/business-team-investment-entrepreneur-trading-discussing-and-analysis-graph-stock-market-trading-stock-chart-concept-1089940388-acef8549576a4d918cb157c6c88ec8a1.jpg "Introduction to Phantom Stocks and SARs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-991180154-aad62bea33e2473a808a24eb81b8e068.jpg "How the Minimum Wage Impacts Unemployment")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1427847593-c401663a1b954137ac712a650eea3a95.jpg "Borrowing from Your Retirement Plan")